ISRCTN ISRCTN15090567
DOI https://doi.org/10.1186/ISRCTN15090567
ClinicalTrials.gov number NCT02300701
Secondary identifying numbers 17968
Submission date
03/12/2014
Registration date
03/12/2014
Last edited
26/10/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Up to 1 child in 5 has eczema. Many of these children are successfully treated by creams or medicines. However, a small number of these children have such severe eczema that the available medicines are unable to control it. Other children have side effects from the medication, so that they cannot continue to take it. The aim of this study is to see if a new medication, Xolair (also known as omalizumab or anti-IgE), can help children with severe eczema, who have not responded to other available treatments.

Who can participate?
Children aged 4-19 with severe eczema that is not controlled by available medications.

What does the study involve
Participants are randomly allocated into one of two groups. Those in group 1 receive Xolair for 6 months. Those in group 2 are given a placebo for 6 months. All participants are then monitored for a further 6 months after treatment.

What are the possible benefits and risks of participating?
Ultimately it is hoped that the treatments in this study will help children with eczema. However, there is no guarantee that a child’s eczema will get better if they participate in the study. The information we get from this study may, however, help to find better treatments for children with severe eczema with fewer side effects. Participants have to make a number of visits to hospital for the treatment. They also undergo allergy tests and other tests.

Where is the study run from?
Evelina Children’s Hospital, St Thomas’ Hospital, London (UK)

When is the study starting and how long is it expected to run for?
November 2014 to July 2016

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Dr Susan Chan

Contact information

Dr Susan Chan
Scientific

Guy's and St. Thomas' NHS Foundation trust
St Thomas's Hospital
249 Westminster Bridge Road
London
SE1 7EH
United Kingdom

Study information

Study designRandomised interventional study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Community
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleThe role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema
Study acronymADAPT
Study objectivesThis research aims to establish the role of anti-IgE therapy in children with severe eczema
Ethics approval(s)NRES Committee London - Westminster, 07/07/2011, ref. 11/LO/0123
Health condition(s) or problem(s) studiedTopic: Children; Subtopic: Allergy, Infect &Immun; Disease: All Diseases; Topic: Dermatology; Subtopic: Dermatology; Disease: Dermatology
InterventionPatients will receive anti-IgE/Xolair/omalizumab or placebo for 24 weeks, and will be followed up for a further 24 weeks. Dosage and frequency of treatment will be determined by the standard manufacturer’s dosing tables, and will be administered by subcutaneous injection.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Omalizumab
Primary outcome measureEczema severity; Timepoint(s): End of treatment
Secondary outcome measuresN/A
Overall study start date20/11/2014
Completion date01/07/2016

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsPlanned Sample Size: 62; UK Sample Size: 62
Total final enrolment62
Key inclusion criteria1. Children between the ages of 4-19 years at the time of enrolment into the trial
2. Severe eczema with
2.1. an objective SCORAD (a validated eczema severity score) of over 40
2.2. in a patient unresponsive to optimal topical therapy (potent topical steroids and topical calcineurin inhibitors)
2.3. in whom there is no impression of lack of compliance
2.4. with a (C)DLQI score of ≥10
2.5. and in whom active infection has been ruled out and/or adequately treated
3. Raised SpIgE (>0.35 IU/ml)or SPT (>3mm)to at least 1 food allergen or 1 aeroallergen
AND/OR
4. Clinical impression that allergic exposures cause worsening eczema.
5. Total IgE level >300 kU/l.
6. Clinically proven IgE-mediated allergic disease including at least 1 of the following:
6.1. Immediate hypersensitivity to a food as proven by raised specific IgE (SpIgE) or skin prick test (SPT) greater than the 95% positive predictive value or ≥8mm, or a positive double blind placebo controlled food challenge,
6.2. Allergic rhinoconjunctivitis as defined by sensitisation to a respiratory allergen and clinical history of rhinoconjunctivitis symptoms when exposed to the relevant allergen
6.3. Allergic asthma: a history of cough, wheeze, or shortness of breath that
6.3.1. Was responsive to therapy with bronchodilators on two or more occasions in the previous 24 months
6.3.2. Required one visit to a physician in the previous 24 months
6.3.3. Occurred during the night, during early morning, or upon exercising in the intervals between exacerbations at any time in the previous 12 months
6.3.4. Where allergic exacerbations can be clinically related to an allergen exposure WITH a corresponding positive SPT or SpIgE to allergen
7. Written informed consent to participate.
Key exclusion criteria1. Children and/or families who are unable to comply with the regime of 24 weekly injections and clinic visits
2. Evidence of underlying immune compromise, autioimmune disease, immune complex mediated conditions
3. Malignancy or a history of malignancy
4. Preexisting hepatic or renal impairment
5. Known cardiovascular or ischaemic cerebrovascular abnormality
6. Other serious or uncontrolled systemic disease
7. Pregnancy or lactation
8. Known history of hypersensitivity or anaphylaxis to anti-IgE injections or its constituents
9. Insufficient understanding of the trial assessments
10. Participation in a CTIMP in the previous 60 days or (if known) 4 half-lives of the relevant medication, whichever is the greater. In this case, entry may be delayed until the appropriate time
11. Investigator feels that there is a good clinical reason why the child would be unsuitable to participate in the study
Date of first enrolment20/11/2014
Date of final enrolment01/01/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Guy's and St. Thomas' NHS Foundation Trust
St Thomas's Hospital
249 Westminster Bridge Road
London
SE1 7EH
United Kingdom

Sponsor information

Guy's & St Thomas' NHS Foundation Trust & King's College London (Comprehensive)
Hospital/treatment centre

Imaging Sciences
The Rayne Institute
Lambeth Wing - 4th floor
St Thomas' Hospital
London
SE1 7EH
England
United Kingdom

ROR logo "ROR" https://ror.org/00j161312

Funders

Funder type

Government

National Institute for Health Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planTo be confirmed at a later date
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 22/03/2017 Yes No
Statistical Analysis Plan statistical analysis plan 23/05/2017 No No
Results article results 25/11/2019 07/08/2020 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

26/10/2020: The NCT code has been added.
07/08/2020: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.
30/05/2017: Publication reference added.
24/03/2017: Publication reference added.